References
- Rubin AI, Chen EH, Ratner D. Basal-cell carcinoma. N Engl J Med. 2005;353:2262–9
- Dandurand M, Petit T, Martel P, et al. Management of basal cell carcinoma in adults: clinical practice guidelines. Eur J Dermatol. 2006;16:394–401
- David CV, Nguyen H, Goldenberg G. Imiquimod: a review of off-label clinical applications. J Drugs Dermatol. 2011;11:1300–6
- Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low frequency dosing with and without occlusion. Br J Dermatol. 2002;147:1227–36
- Geisse J, Caro I, Lindholm J, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III randomized vehicle controlled studies. J Am Acad Dermatol. 2004;50:722–33
- Gollnick H, Barona CG, Frank RG, et al. Recurrence rate of superficial basal cell carcinoma following successful treatment with imiquimod 5% cream: conclusion of a 5 year long term follow up study in Europe. Eur J Dermatol. 2008;18:677–82
- Schulze HJ, Cribier B, Requena L, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152:939–47
- Lacarrubba F, Potenza MC, Gurgone S, et al. Successful treatment and management of large superficial basal cell carcinomas with topical imiquimod 5% cream: a case series and review. J Dermatol Treat. 2011;22:353–8
- Kirby JS, Miller CJ. Intralesional chemotherapy for nonmelanoma skin cancer: a practical review. J Am Acad Dermatol. 2010;63:689–702
- Vanalocha F, Dauden E, Badia X, et al. Cost-effectiveness of treatment of superficial basal cell carcinoma: surgical excision vs. imiquimod 5% cream. Br J Dermatol. 2007;156:769–71